Marker Therapeutics (MRKR) Misses Q3 EPS by 12c

Marker Therapeutics (NASDAQ: MRKR) reported Q3 EPS of ($0.12). Revenue for the quarter came in at $1.23 million.

For earnings history and earnings-related data on Marker Therapeutics (MRKR) click here.

You May Also Be Interested In

• Moomoo launches paid trading toolkit called Moomoo Engine
• Goldman's Garrett sees investors dialing back tech exposure into H2
• Cisco Partners With College Board To Launch AP Cybersecurity and Expand Career-Connected Learning